← All trials
NCT04712864
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 13, 2021
- Primary completion
- Dec 31, 2023
- Completion date
- Dec 31, 2025
- First posted
- Jan 15, 2021
- Last posted
- Sep 17, 2021
- Enrollment
- 50
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Legend Biotech USA IncLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.